Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000994023 | SCV001147310 | uncertain significance | not provided | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001585900 | SCV001821753 | uncertain significance | Retinitis pigmentosa 20 | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001593170 | SCV001821864 | uncertain significance | Leber congenital amaurosis 2 | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002549849 | SCV003270481 | uncertain significance | Leber congenital amaurosis 2; Retinitis pigmentosa 20 | 2022-06-20 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 183 of the RPE65 protein (p.Ile183Val). This variant is present in population databases (no rsID available, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with RPE65-related conditions. ClinVar contains an entry for this variant (Variation ID: 806151). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Breakthrough Genomics, |
RCV000994023 | SCV005186752 | uncertain significance | not provided | criteria provided, single submitter | not provided |